Baird analyst Brian Skorney says an additional $200M investment by Nestle Health Science (NSRGY) removes the funding overhang on shares of Aimmune Therapeutics (AIMT). The analyst estimates the combination of the raise with Aimmune's existing cash and KKR credit facility should give the company access to over $450M. This is more than enough to fund the launch of Palforzia and "get to a point that settles the bull/bear launch debate," Skorney tells investors in a research note. A capital raise now won't be a place for the company's short interest to cover, adds the analyst. Skorney is positive on the news and keeps an Outperform rating on Aimmune with a $64 price target.